NICE - Endorsed Technology Appraisals 2024/2025
It is important to note that the advice contained within the guidance does not override or replace the individual responsibility of health professionals to make appropriate decisions in the circumstances of their individual patients, in consultation with the patient and/or guardian or carer. This would, for example, include situations where individual patients have other conditions or complications that need to be taken into account in determining whether the NICE guidance is fully appropriate in their case.
Technology Appraisals Endorsement Process
The Department has reviewed its process for the endorsement, implementation, monitoring and assurance of NICE Technology Appraisals in Northern Ireland. The new arrangements are detailed in following circulars, which is effective from 18th December 2013;
NICE Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 02/13.
For information, details of the previous arrangement can be found on the following circular;
NICE Technology Appraisals and Clinical Guidelines – New Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland – HSC (SQSD) 04/11
2024/2025
The following technology appraisals have been endorsed during 2024/25. Information on technology appraisals endorsed in previous years can be found on the homepage.
March 2025
TA1043 - Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection Note this guidance updates and replaces NICE Technology Appraisal TA761, endorsed by the DoH in February 2022.
TA1042 - Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer Note - this guidance updates and replaces NICE Technology Appraisal TA760, endorsed by the DoH in February 2022
TA1038 - Selpercatinib for advanced thyroid cancer with RET alterations after treatment with a targeted cancer drug in people 12 years and over Note this guidance updates and replaces NICE Technology Appraisal TA742, endorsed by the DoH in November 2021.
TA1037 - Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer
February 2025
TA1031 - Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over
January 2025
TA1027 - Tebentafusp for treating advanced uveal melanoma
TA1026 - Tirzepatide for managing overweight and obesity
TA1025 - Ublituximab for treating relapsing multiple sclerosis
December 2024
TA1022 - Bevacizumab gamma for treating wet age-related macular degeneration
TA1021 - Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer Note this guidance updates and replaces NICE Technology Appraisal TA529, endorsed by the DoH in February 2019
TA1020 - Eplontersen for treating hereditary transthyretin-related amyloidosis
TA989 - Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B
TA1019 - Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over
TA1018 - Fedratinib for treating disease-related splenomegaly or symptoms in myelofibrosis
TA1016 - Elafibranor for previously treated primary biliary cholangitis
TA1014 - Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer
November 2024
TA1012 - Avapritinib for treating advanced systemic mastocytosis
TA1011 - Belzutifan for treating tumours associated with von Hippel-Lindau disease
TA1010 - Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria
October 2024
TA1007 - Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer Note this guidance updates and replaces NICE Technology Appraisal TA611, endorsed by the DoH in November 2019
September 2024
TA1001 - Zanubrutinib for treating marginal zone lymphoma after anti-CD20-based treatment
TA1000 - Iptacopan for treating paroxysmal nocturnal haemoglobinuria
TA999 - Vibegron for treating symptoms of overactive bladder syndrome
TA998 - Risankizumab for treating moderately to severely active ulcerative colitis
TA997 - Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma Note this guidance partially updates NICE Technology Appraisal TA737, endorsed by the DoH in November 2021
TA996 - Linzagolix for treating moderate to severe symptoms of uterine fibroids
TA995 - Relugolix for treating hormone-sensitive prostate cancer
TA991 - Abaloparatide for treating osteoporosis after menopause
TA993 - Burosumab for treating X-linked hypophosphataemia in adults
August 2024
TA990 - Tenecteplase for treating acute ischaemic stroke
TA988 - Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis Note this guidance updates and replaces NICE Technology Appraisal TA398, endorsed by the DoH in August 2016
TA986 - Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over
July 2024
TA985 - Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma Note this guidance partially updates NICE Technology Appraisal TA688, endorsed by the DoH in April 2021
TA984 - Tafamidis for treating transthyretin amyloidosis with cardiomyopathy Note this guidance updates and replaces NICE Technology Appraisal TA696, endorsed by the DoH in June 2021.
June 2024
TA981 - Voxelotor for treating haemolytic anaemia caused by sickle cell disease
TA979 - Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation
TA975 - Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under Note this guidance updates and replaces NICE Technology Appraisal TA554, endorsed by the DoH in March 2019.
TA974 - Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma
TA973 - Atogepant for preventing migraine
TA971 - Remdesivir and tixagevimab plus cilgavimab for treating COVID-19
May 2024
TA967 - Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and over Note this guidance partially updates and replaces NICE Technology Appraisal TA540, endorsed by the DoH in March 2019.
TA964 - Cabozantinib with nivolumab for untreated advanced renal cell carcinoma
April 2024
TA963 - Dostarlimab with platinum-based chemotherapy for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency Note this guidance has been updated and replaced by TA1064 - Dostarlimab with platinum-based chemotherapy for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency, endorsed by the DoH in June 2025
TA962 - Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy Note this guidance updates and replaces NICE Technology Appraisal TA598, endorsed by the DoH in September 2019.
TA958 - Ritlecitinib for treating severe alopecia areata in people 12 years and over
TA957 - Momelotinib for treating myelofibrosis-related splenomegaly or symptoms
TA955 - Dupilumab for treating moderate to severe prurigo nodularis
TA953 - Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema Note this guidance updates and replaces NICE Technology Appraisals TA613, endorsed by the DoH in December 2019 and TA301, endorsed by the DoH in December 2013.